Influx Healthtech IPO Details
The key details of Influx Healthtech’s IPO are outlined below, covering all crucial aspects from price range to investment requirements and regulatory documents.
| IPO Size | ₹58.57 Cr |
| Price Range | ₹91 - ₹96 |
| Retail Quota | 35% |
| QIB Quota | 50% |
| NII Quota | 15% |
| Employee Discount | -- |
| Listing at | NSE and BSE |
| Minimum Quantity | 1200 |
| Investment (cut-off price) | ₹1,15,200 |
| Pre IPO Promotor Holding | 99.85% |
| Post IPO Promotor Holding | 73.53% |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Influx Healthtech IPO Timelines
The IPO process for Influx Healthtech includes key dates for participants to know. The timeline allows for strategic planning and participation, helping investors stay informed and engaged throughout the entire process.
18/06/2025
Start Date20/06/2025
End Date24/06/2025
Refund Initiation24/06/2025
Credit of Shares to Demat Ac25/06/2025
Listing DateInflux Healthtech IPO Lot Size
The Influx Healthtech IPO has a fixed lot size of 1,200 shares, at an upper price band of ₹96 per share, requiring ₹115,200 per lot for retail investors. For HNI investors, the minimum application is 2,400 shares (2 lots) amounting to ₹230,400.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 1200 | ₹1,15,200 |
| Retail Maximum | 1 | 1200 | ₹1,15,200 |
| HNI Minimum | 2 | 2400 | ₹2,30,400 |
Influx Healthtech IPO Subscription Status
The subscription status for Influx Healthtech IPO shows market demand across different investor categories, providing valuable insights into the offering’s performance. You can track real-time subscription data below.
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
| 137.87x | 481.10x | 117.68x | -- | 201.35x |
IPO Performance on Listing Day
On the listing day (June 25, 2025), Influx Healthtech made a strong debut on the stock exchange. The stock opened at ₹132.50, delivering an impressive premium of 38% over its issue price of ₹96. During the trading session, the stock touched a high of ₹135.85 before witnessing some profit booking that brought it to a low of ₹125.90. The shares concluded their first trading day at ₹126.20, securing a substantial gain of 31.5% over the issue price, reflecting solid investor confidence in this healthcare technology company.
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹132.50 | ₹126.20 | ₹135.85 | ₹125.90 |
Influx Healthtech IPO Company Financials
Influx Healthtech IPO reports robust performance in FY2025 with Total Income of ₹104.99 crores, managing expenses at ₹87.11 crores, and achieving a strong PAT (Profit After Tax) of ₹13.37 crores, demonstrating significant growth potential ahead of its public offering.
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2023 | ₹76.06 | ₹66.32 | ₹7.20 |
| FY 2024 | ₹100.02 | ₹85.08 | ₹11.13 |
| FY 2025 | ₹104.99 | ₹87.11 | ₹13.37 |
About Company
Influx Healthtech Limited, incorporated in September 2020 and based in Mumbai, is a contract manufacturing company with a strong focus on the healthcare sector. Operating as a CDMO (Contract Development and Manufacturing Organization), the company provides end-to-end services including product development, production, and regulatory support. Its client base spans several industries, including nutraceuticals and cosmetics, allowing companies to focus on formulation and commercialization while outsourcing manufacturing needs. Influx Healthtech runs three manufacturing facilities in Thane, Maharashtra, covering areas of approximately 9,676, 13,000, and 14,000 square feet respectively. As of June 11, 2025, the company employs 163 permanent staff members.
The company’s product portfolio is extensive, offering everything from tablets, capsules, powders, and liquid orals to cosmetics like skincare and beard care products. It also produces Oral Dispersible Films (ODFs), effervescent tablets, softgels, candies, jellies, and gym supplements. Additionally, it serves the veterinary and homecare markets. Influx Healthtech is certified with GMP, HACCP, ISO 22000, and Halal standards, and its facilities are equipped with advanced machinery and a dedicated quality control department. This diversified product range and robust manufacturing infrastructure position the company as a reliable partner in both domestic and international healthcare markets.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 2020 | Healthcare | Dr. Munir Chandniwala |
Know Before Investing
Influx Healthtech IPO Strengths
- Influx Healthtech has demonstrated robust revenue growth, with a 31.44% increase in revenue from ₹76.05 crore in FY23 to ₹99.97 crore in FY24, alongside rising profitability.
- The company maintains strong net profit margins (11.2% in FY24) and operating profit margins (16.9% in FY24), indicating efficient operations and cost management.
- Established in 2020, Influx Healthtech has quickly grown into a key player in the contract development and manufacturing organization (CDMO) sector, serving diverse industries.
- The company operates across nutraceuticals, cosmetics, veterinary feed supplements, ayurvedic, and homecare products, reducing reliance on any single segment.
- Influx Healthtech serves reputable clients such as Bling Brands Private Limited and Evoq Business Ventures LLP, showcasing its credibility and market reach.
- The health and wellness sector, especially CDMOs and nutraceuticals, is experiencing increased demand, providing a favorable environment for Influx Healthtech’s expansion.
Influx Healthtech IPO Risks
- The company operates in a sector with evolving regulations, and any changes or non-compliance could negatively impact operations and profitability.
- The company’s plans for expansion and new facilities may face delays, cost overruns, or operational setbacks, affecting growth and financial performance.
- The health and wellness sector is highly competitive, and new entrants or price wars could erode market share and margins.
- Broader economic downturns, shifts in consumer preferences, or adverse sector trends could negatively impact demand for the company’s products and services.
- Dependency on major clients like Bling Brands and Evoq Business Ventures exposes revenue stability to client retention risks.
- Operating in the highly regulated healthcare CDMO sector exposes the company to potential compliance costs and operational disruptions.
- Planned manufacturing facility expansions carry risks of project delays and cost overruns impacting growth projections.
Swot Analysis for Influx Healthtech IPO
Strengths
Robust Financial Growth, Sectoral Tailwinds, Government Policy Support
Weaknesses
Regional Concentration, Dependence on Sector Performance, Lack of Brand Recognition
Opportunities
Sectoral Expansion, Government Healthcare Push, Technology Adoption
Threats
Intense Competition, Regulatory and Compliance Risks, Raw Material/Input Cost Volatility
Company Details
Influx Healthtech Limited
109, Ghanshyam Enclave Premises Co-op Soc Plot No. 856, Laljipada, Kandivali West, Mumbai – 400067 Maharashtra, India
Phone: +91 7045997809
Email: cs@influxhealthtech.com
Website: https://influxhealthtech.com/
IPO Registar Details
Maashitla Securities Private Limited
Phone: +91-11-45121795-96
Email: investor.ipo@maashitla.com
Website: https://maashitla.com/allotment-status/public-issues
FAQs
The key objectives of Influx Healthtech IPO are:
- Funding capital expenditure requirements for setting up of manufacturing facility for Nutraceutical Division
- Funding capital expenditure requirements for setting up of manufacturing facility for Veterinary Food Division
- Purchase of Machineries for Homecare and Cosmetic Division
- General corporate purposes
Rarever Financial Advisors Pvt. Ltd. is the book-running lead managers for the Influx Healthtech IPO.
Influx Healthtech’s IPO reflects strong growth potential, highlighted by its healthy revenue trajectory—from ₹76.06 crore in 2023 to ₹104.99 crore in 2025. The significant jump between 2023 and 2024 signals strong market traction, while the steady rise in 2025 suggests business stability and maturity. Operating in a rapidly expanding healthtech sector, Influx is well-positioned to leverage digital healthcare trends and scale further.
The issue price for the Influx Healthtech IPO is set between ₹91 to ₹96 per share.
To invest in one lot of Influx Healthtech IPO, you need ₹1,09,200 at the lower price band (₹91 per share) or ₹1,15,200 at the upper price band (₹96 per share) for a lot size of 1200 shares.
Influx Healthtech IPO shares are scheduled to be listed on the National Stock Exchange (NSE) on June 25, 2025.
Refund/unblocking of funds for Influx Healthtech IPO will begin on June 24, 2025. ASBA/UPI blocks will be removed within 1 working day.
You can sell shares your Influx Healthtech IPO shares on listing day (June 25, 2025) after they are credited to your demat account. If you want to sell in the pre-open market, the timing for that session is from 9:00 AM to 9:15 AM. Otherwise, you can sell after 10:00 AM during regular trading hours.